<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539327</url>
  </required_header>
  <id_info>
    <org_study_id>GEICO 87-R</org_study_id>
    <nct_id>NCT04539327</nct_id>
  </id_info>
  <brief_title>Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study</brief_title>
  <official_title>Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Investigación en Cáncer de Ovario</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clovis Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Español de Investigación en Cáncer de Ovario</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study consists of a retrospective observational, multicenter study in which the&#xD;
      fundamental exposure factor being investigated is a drug (rucaparib).&#xD;
&#xD;
      A clinical database will be built including clinical data in three scenarios of rucaparib&#xD;
      treatment: (1) platinum-sensitive BRCA-mutated patients after progression, (2) maintenance&#xD;
      therapy in patients after a platinum-sensitive relapse in response, and (3) treatment therapy&#xD;
      in BRCA-mutated patients who are currently platinum-resistant.&#xD;
&#xD;
      The specific objectives of the study are:&#xD;
&#xD;
        -  To describe patient characteristics/medical history, safety, efficacy, and dosing of&#xD;
           on-label treatment with rucaparib in real-world patients (real-world data).&#xD;
&#xD;
        -  To describe patient characteristics/medical history, safety, efficacy, and dosing of all&#xD;
           patients treated with rucaparib (including patients with on-label treatment and others)&#xD;
           in real-world patients (real-world data).&#xD;
&#xD;
        -  To show that data obtained in clinical trials could be reproduced in non-screened&#xD;
           patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2020</start_date>
  <completion_date type="Anticipated">July 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 29, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient characteristics and medical history</measure>
    <time_frame>Month 10-12</time_frame>
    <description>Sex, age, mutational status (BRCA 1/2 [germline/somatic] and in other homologous recombination repair (HRR) genes), number of previous relapses, number of previous chemotherapy regimens, types of treatments received (chemotherapy, targeted therapies [bevacizumab, PARP inhibitors (PARPi)]), prior maintenance or with maintenance, treatment-free interval (platinum-based chemotherapy, non-platinum-based chemotherapy, targeted therapy).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rucaparib safety data: Adverse Events</measure>
    <time_frame>Month 10-12</time_frame>
    <description>All rucaparib-related hematological and non-hematological, serious and non-serious adverse events (grade, start date, end date, action taken with rucaparib, outcome). In addition, adverse event treatments will be registered in the study database.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rucaparib efficacy data</measure>
    <time_frame>Month 10-12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rucaparib dosing data</measure>
    <time_frame>Month 10-12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Data reproducibility</measure>
    <time_frame>Month 10-12</time_frame>
    <description>In order to show that data obtained in clinical trials could be reproduced in non-screened patients, the outcomes will be discussed in the context of the results from ARIEL3 trial and the integrated analysis of Study 10 and ARIEL2.</description>
  </primary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Primary Peritoneal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rucaparib</intervention_name>
    <description>Participating local sites (GEICO-associated hospitals with expertise in gynecological cancer management) will enter clinical data of those patients who have previously participated in the rucaparib access program (RAP) in Spain and have given their consent.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult (18 years or more) women diagnosed with high-grade epithelial ovarian, fallopian&#xD;
        tube, or primary peritoneal cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent must be signed by all patients participating in the study who&#xD;
             can be interviewed in the hospital (accessible, alive patients). Informed consent may&#xD;
             not be required from unaccessible patients (dead, lost, etc.) according to ethics&#xD;
             committee permissions and applicable law for retrospective studies in Spain.&#xD;
&#xD;
          2. Histological diagnosis of high-grade epithelial ovarian, fallopian tube, or primary&#xD;
             peritoneal cancer treated in the context of rucaparib access program (RAP) in Spain.&#xD;
&#xD;
          3. Adult women (18 years or more at the time of diagnosis).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Patients without medical record available (lost, empty or unretrievable clinical&#xD;
        information).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alfonso Yubero, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario Lozano Blesa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patricio Ledesma</last_name>
    <phone>+34 971439900</phone>
    <email>ensayos@sofpromed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Torrecárdenas</name>
      <address>
        <city>Almería</city>
        <state>Andalucía</state>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Piedad Reche Molina, Dra.</last_name>
    </contact>
    <investigator>
      <last_name>Piedad Reche Molina, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <state>Andalucía</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bella Pajares Hachero, Dra.</last_name>
      <phone>+34 951 032083</phone>
    </contact>
    <investigator>
      <last_name>Bella Pajares Hachero, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Purificación Estévez García, Dra.</last_name>
      <phone>+34 955 013068</phone>
      <email>puriestevez@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Purificación Estévez García, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisa Calvo García, Dra.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Señora de Valme</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucía</state>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Enrique Robles Barraza, Dr.</last_name>
      <phone>+34 955016189</phone>
      <email>croblesbarraza@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Carlos Enrique Robles Barraza, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Fuentes Pradera, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General San Jorge</name>
      <address>
        <city>Huesca</city>
        <state>Aragón</state>
        <zip>22004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julia Madani Pérez, Dra.</last_name>
      <phone>+34 619375270</phone>
      <email>julimuna@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Julia Madani Pérez, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alfonso Yubero Esteban, Dr.</last_name>
      <phone>+34 976 765746</phone>
      <email>ayuberoe@salud.aragon.es</email>
    </contact>
    <investigator>
      <last_name>Alfonso Yubero Esteban, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irene Torres, Dra.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana María Herrero Ibáñez, Dra.</last_name>
      <phone>+34 976 765500</phone>
      <phone_ext>3827</phone_ext>
      <email>herreroa@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Ana María Herrero Ibáñez, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Eugenia Ortega Izquierdo, Dra.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Álvaro Taus García, Dr.</last_name>
      <phone>+34 93 248 31 37</phone>
      <email>96720@parcdesalutmar.cat</email>
    </contact>
    <investigator>
      <last_name>Álvaro Taus García, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lydia Gaba Garcia, Dra.</last_name>
      <phone>+34932275400</phone>
      <phone_ext>4206</phone_ext>
      <email>lgaba@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Lydia Gaba Garcia, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano De Oncologia</name>
      <address>
        <city>Valencia</city>
        <state>Comunitat Valenciana</state>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ignacio Romero Noguera, Dr.</last_name>
      <phone>+34 96 110 46 25</phone>
      <email>iromero@fivo.org</email>
    </contact>
    <investigator>
      <last_name>Ignacio Romero Noguera, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <state>Comunitat Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Santaballa Bertrán, Dra.</last_name>
      <phone>+34 661 648 789</phone>
      <email>santaballa_ana@gva.es</email>
    </contact>
    <investigator>
      <last_name>Ana Santaballa Bertrán, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Cañabate Arias, Dra.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helena Sélica de la Cueva Sapiña, Dra.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Público Lluis Alcanyis</name>
      <address>
        <city>Xàtiva</city>
        <state>Comunitat Valenciana</state>
        <zip>46800</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmen Salvador Coloma, Dra.</last_name>
      <phone>+34 96 2289968</phone>
      <email>salvador_carcol@gva.es</email>
    </contact>
    <investigator>
      <last_name>Carmen Salvador Coloma, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel Navarro Cortina, Dra.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro López Tendero, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <state>Galicia</state>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuel Constenla Figueiras, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Manuel Constenla Figueiras, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesús Damián Alarcón, Dr.</last_name>
      <email>jesus.alarcon@ssib.es</email>
    </contact>
    <investigator>
      <last_name>Jesús Damián Alarcón, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neus Ferrer Tur, Dra.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julia Calzas Rodríguez, Dra.</last_name>
    </contact>
    <investigator>
      <last_name>Julia Calzas Rodríguez, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Sofía</name>
      <address>
        <city>San Sebastián de los Reyes</city>
        <state>Madrid</state>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>María Merino Salvador, Dra.</last_name>
      <email>mmerinos.hulp@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>María Merino Salvador, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Araba Txagorritxu</name>
      <address>
        <city>Gasteiz / Vitoria</city>
        <state>País Basco</state>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Gutiérrez Toribio, Dra.</last_name>
    </contact>
    <investigator>
      <last_name>Maria Gutiérrez Toribio, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Madrid</city>
        <zip>28027</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>María Luísa Sánchez Lorenzo, Dra.</last_name>
      <phone>+34 913 53 19 20</phone>
      <email>lsanchez@unav.es</email>
    </contact>
    <investigator>
      <last_name>María Luísa Sánchez Lorenzo, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raúl Márquez Vázquez, Dr.</last_name>
      <phone>+34 917 878 600</phone>
      <phone_ext>1334</phone_ext>
      <email>mmarquezv@mdanderson.es</email>
    </contact>
    <investigator>
      <last_name>Raúl Márquez Vázquez, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel Gallegos Sancho, Dra.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Marquina Ospina, Dra.</last_name>
      <phone>+34 636098568</phone>
      <email>gloriamarquina@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gloria Marquina Ospina, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victoria Casado Echarren, Dra.</last_name>
    </contact>
    <investigator>
      <last_name>Victoria Casado Echarren, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis Manuel Manso Sánchez, Dr.</last_name>
      <phone>+34 91 390 80 03</phone>
      <phone_ext>8003</phone_ext>
      <email>luigimanso@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Luis Manuel Manso Sánchez, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Lema Roso, Dra.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Sánchez de Torre, Dra.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva María Ciruelos Gil, Dra.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pablo Tolosa Ortega, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncológico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arántzazu Barquin Garcia, Dra.</last_name>
      <email>abarquin@hmhospitales.com</email>
    </contact>
    <investigator>
      <last_name>Arántzazu Barquin Garcia, Dra.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rucaparib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rucaparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

